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Abstract
Studies in rodents indicate that diets deficient in omega-3 polyunsaturated fatty acids (n–3 PUFA) lower dopamine
neurotransmission as measured by striatal vesicular monoamine transporter type 2 (VMAT2) density and amphetamine-
induced dopamine release. This suggests that dietary supplementation with fish oil might increase VMAT2 availability,
enhance dopamine storage and release, and improve dopamine-dependent cognitive functions such as working memory.
To investigate this mechanism in humans, positron emission tomography (PET) was used to measure VMAT2 availability pre-
and post-supplementation of n–3 PUFA in healthy individuals. Healthy young adult subjects were scanned with PET using
[11C]-(+)-a-dihydrotetrabenzine (DTBZ) before and after six months of n–3 PUFA supplementation (Lovaza, 2 g/day
containing docosahexaenonic acid, DHA 750 mg/d and eicosapentaenoic acid, EPA 930 mg/d). In addition, subjects
underwent a working memory task (n-back) and red blood cell membrane (RBC) fatty acid composition analysis pre- and
post-supplementation. RBC analysis showed a significant increase in both DHA and EPA post-supplementation. In contrast,
no significant change in [11C]DTBZ binding potential (BPND) in striatum and its subdivisions were observed after
supplementation with n–3 PUFA. No correlation was evident between n–3 PUFA induced change in RBC DHA or EPA levels
and change in [11C]DTBZ BPND in striatal subdivisions. However, pre-supplementation RBC DHA levels was predictive of
baseline performance (i.e., adjusted hit rate, AHR on 3-back) on the n-back task (y = 0.19+0.07, r2 = 0.55, p = 0.009). In
addition, subjects AHR performance improved on 3-back post-supplementation (pre 0.6560.27, post 0.8060.15, p = 0.04).
The correlation between n-back performance, and DHA levels are consistent with reports in which higher DHA levels is
related to improved cognitive performance. However, the lack of change in [11C]DBTZ BPND indicates that striatal VMAT2
regulation is not the mechanism of action by which n–3 PUFA improves cognitive performance.
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Introduction
Previous studies in humans suggest that n–3 PUFA deficiency is
associated with impairment in mood [1] and cognitive functioning
[2]. Some [3–5], but not all studies [6–9] suggest that the
supplementation of n–3 PUFA in several neuropsychiatric
disorders such as mood disorders, schizophrenia and attention
deficit hyperactivity disorder holds promise as a primary or
adjunctive therapy. Mechanistic studies are discovering roles of n–
3 PUFAs in modulation of neuronal membrane fluidity and
permeability, enhancement of monoamine transmission, alteration
of the activity of protein kinases and phosphatidylinositol-
associated second messenger systems, alteration in gene expression
and decreased oxidative stress and inflammation. Nonetheless,
how these actions relate to the putative effects of n–3 PUFA on
cognitive functioning and affective symptoms is unknown.
Basic science investigations involving rodents indicate that n–3
PUFA deficiency alters the transmission of monoamines such as
dopamine and serotonin in the brain [10]. For example, studies
that have measured stimulant-induced dopamine release report
35% and 60–80% reductions in dopamine release in the ventral
striatum and prefrontal cortex respectively in n–3 PUFA deficient
animals relative to controls [11,12]. Also compelling are the
tyramine-induced dopamine release microdialysis studies that have
reported a 90% reduction in prefrontal cortical dopamine
transmission [13,14] and the cerebral monoamine quantitation
studies that have reported a 40 to 75% reduction in prefrontal
dopamine in n–3 PUFA deficient animals relative to controls
[15,16]. In addition, rodent studies are consistent in reporting a 25
to 60% reduction in the VMAT2 density in the prefrontal cortex
and ventral striatum in n–3 PUFA deficient animals relative to
controls [11,12,14,17]. Since most of these studies involved
pregnant rodents and pups the effects of n–3 PUFA supplemen-
tation on dopamine in a mature animal/healthy human are not
known. Nevertheless, as VMAT2 regulates the size of the vesicular
dopamine pool available for release into the synapse, it is plausible
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that n–3 PUFA increases dopamine transmission by increasing the
number of dopamine storage vesicles and associated VMAT2.
Therefore it is tempting to speculate that dietary supplementation
with fish oil enriched in n–3 PUFA increases VMAT2 availability,
in turn enhancing dopamine storage and release and improving
dopamine-dependent cognitive and mood functions in a broad
array of neuropsychiatric disorders.
To evaluate this hypothesis we evaluated 11 healthy individuals
with the selective VMAT2 PET radioligand, [11C]DTBZ both
before and after six-months of n–3 PUFA supplementation
(Omega-3-acid ethyl esters, Lovaza 2 g/day, which contains
DHA 750 mg/d and EPA 930 mg/d). Our primary hypothesis
was that n–3 PUFA would increase VMAT2 availability
(measured as [11C]DTBZ binding potential, BPND) in healthy
individuals after six months of supplementation. In addition, we
hypothesized that this increased availability of VMAT2 will lead to
greater vesicular dopamine stores and improve dopamine-depen-
dent working memory, which was measured using a verbal n-back
task and three working memory loads (1-back, 2-back and 3-back).
Materials and Methods
Ethics Statement
The study was conducted following the approvals of the
University of Pittsburgh Institutional Review Board and Radio-
active Drug Research Committee. All subjects provided written
informed consent.
Study criteria for healthy controls were [1] males or females
between 18 and 25 years old, of all ethnic and racial origins; [2] no
past or current Diagnostic and Statistical Manual of Mental
Disorders IV criteria for psychiatric disorders, including addiction
to drugs, alcohol or nicotine (as confirmed by urine drug screen at
screening) [3] not currently on any prescription or over the
counter medications including vitamins or herbal supplements; [4]
female subjects were not currently pregnant and used of an
effective birth control such as intrauterine contraceptive device,
oral contraceptive pills during the entire course of the study; [5] no
current or past severe medical or neurological illnesses (including
glaucoma, seizure disorders, a focal finding on magnetic resonance
imaging, MRI such as stroke or tumor) as assessed by a complete
medical assessment; [6] no hypersensitivity to fish or shell fish; [7]
no history of significant radioactivity exposure (nuclear medicine
studies or occupational exposure); [8] no metallic objects in the
body that are contraindicated for MRI; [9] no drinking of more
than two standard alcoholic drinks per day; [10] no first degree
relatives with an Axis I psychiatric disorder; [11] no consumption
of fish more than twice a month or currently on fish oil
supplements.
A total of thirteen subjects who met inclusion/exclusion criteria
(as determined by a structured clinical interview for DSM IV,
medical evaluation, electrocardiogram, and routine blood and
urine tests, which included a drug screen and pregnancy test) were
enrolled to participate in the study that was conducted in the
outpatient setting. All enrolled subjects underwent a pre-supple-
mentation [11C]DTBZ PET scan, n-back task and RBC mem-
brane extraction for fatty acid analysis after an overnight fast.
Then, subjects were supplemented with n–3 PUFA (Lovaza), 2 g
once daily for six months after which they were eligible for the
post-supplementation evaluations (conducted a minimum of five
months and maximum of 6 months after n–3 PUFA supplemen-
tation), which included a repeat [11C]DTBZ PET scan, n-back
task and RBC for fatty acid analysis. Subjects were monitored on a
monthly basis during the n–3 PUFA supplementation period for
subjective complaints, medication adherence (via pill counts), illicit
drug abuse and pregnancy. In addition to this subjects underwent
a complete blood cell count, liver function test, fasting lipid profile
and RBC for fatty acid analysis at 1-month, 3-months, 5-months
to monitor for abnormal lab results (such as elevations in liver
function tests and low-density lipoproteins and reduction in
platelet count) and confirmed adherence to n–3 PUFA. The
monitoring led to discontinuation on n–3 PUFA supplementation
in two individuals –one for elevated low-density lipoproteins
(193 mg/dl) and another for low platelet counts (120,000/mL) at 1-
month and 5-months post-supplementation respectively (these
abnormal laboratory values reverted back to normal range after
discontinuation in both these subjects). Thus, the final sample
includes pre- and post-supplementation data in only 11 out of the
13 enrolled subjects.
RBC Fatty Acid Composition
Fasting blood samples were processed for the separation of RBC
membranes using previously methods and stored at 280 degree
Celsius [18]. These frozen RBC samples were analyzed for fatty
acid composition using gas chromatography [19]. Individual
PUFA levels are expressed as percentages of the total fatty acid
pool (weight or mol %).
Working Memory Assessment
We chose to assess verbal working memory based on a previous
study that showed a relationship between this neurocognitive
domain and serum DHA [2]. The choice was also driven by the
literature that supports a role for dopamine in working memory
[20–23]. Working memory assessment was performed using a
verbal n-back task that used three loads of working memory (1-
back, 2-back and 3-back) consistent with that previously reported
in [20]. The outcome measure for the n-back was the adjusted hit
rate (AHR, range 21 to 1), which was calculated as the difference
between hit rate (correct responses/number of targets, range 0 to
1) and error rate (errors/number of non targets, range 0 to 1).
[11C]DTBZ PET Imaging
Prior to PET imaging, a magnetization prepared rapid gradient
echo structural MRI scan was obtained using a Siemens 3 Tesla
Trio scanner for determination of regions of interest.
[11C]DTBZ was synthesized using the methodology reported
previously by Kilbourn, et al. [24]. PET imaging sessions were
conducted with the ECAT EXACT HR+ camera. [11C]DTBZ
was injected as a bolus plus constant infusion consistent with that
reported in [25,26] because this infusion paradigm allows for
radioactivity to be measured at true equilibrium, thereby
eliminating the need for invasive arterial catheterization (i.e., the
amount of radiotracer in the region of interest, reference region,
arterial and venous compartments are at equilibrium). Briefly,
55% of the [11C]DTBZ dose (, 15 mCi) was administered as an
intravenous bolus injection over the first 30 seconds, while the
remaining 45% of the dose was continuously infused over the next
60 minutes. This infusion ratio allowed for [11C]DTBZ to reach
steady state thirty minutes after the beginning of the bolus plus
constant infusion [25,26]. Following a 10 minute transmission
scan, emission data were then collected in 3D mode from time,
t = 30 to 60 minutes, relative to the start of the bolus plus constant
infusion in a series of six consecutive 5-minute frames to
correspond to steady state concentration for [11C]DTBZ. In
addition, four venous blood samples (collected at time= 30, 40, 50
and 60 min) were obtained to measure plasma concentration of
[11C]DTBZ as described in [27]. Parent compound plasma
concentrations in these four samples were averaged to obtain
[11C]DTBZ concentration at steady state (CSS, mCi/mL). Plasma
Omega-3 Fatty Acid Supplementation and VMAT2
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clearance (CL, L/h) was calculated as the rate of infusion/CSS and
the free fraction (fp) was measured using previously described
methods [26,28,29].
All region drawing and image analysis was performed with
MEDx (Sensor Systems, Inc., Sterling, Virginia) and SPM2.
Regions of interest were drawn on the MRI and transferred to the
co-registered PET scan. The primary region of interest, the
striatum was divided into five anatomical and three functional
subdivisions using criteria outlined in [30]. The three functional
subdivisions of the striatum included the limbic striatum (ventral
striatum), the associative striatum (which, included the precom-
missural caudate, precommissural putamen and postcommissural
caudate) and sensori-motor striatum (postcommissural putamen).
The occipital cortex was used as the reference region [26,28].
Correction for head movement and co-registration of the PET
data to the MR were done using methods described in [31].
In this section we use the consensus nomenclature for in vivo
imaging of reversibly binding radioligands to describe all outcome
measures [32]. The regional tissue distribution volume (VT ROI,
mL/cm3) defined as the ratio of [11C]DTBZ concentration in the
region of interest (CT, mCi/cm
3) to the concentration of un-
metabolized [11C]DTBZ in venous plasma (CSS, mCi/g) at
equilibrium was derived as.
VT~CT=CSS:
The concentration of VMAT2 is negligible in the occipital
cortex [26,28], such that only free and nonspecifically bound
radiotracer is considered to contribute to VT in the occipital cortex
(VT OCC ). Thus, VT OCC was assumed to be equal to the non-
displaceable distribution volume (VND).
VMAT2 availability in the striatal regions of interest was
estimated as [11C]DTBZ BPND, i.e., binding potential relative to
non-displaceable uptake. This was computed as.
VTROI{VTOCC
VTOCC
~fND~
Bavail
KD
where fND is the free fraction of radiotracer in brain expressed
relative to the non-displaceable concentration (fND = fp/VND),
Bavail is the density of VMAT2 available to bind to [
11C]DTBZ in
vivo and KD is the equilibrium disassociation constant of
[11C]DTBZ.
The effect of n–3 PUFA supplementation on VMAT2
availability was calculated as the relative change in BPND (%).
DBPND~
BPND post supplementation{BPND pre supplementation
BPND pre supplementation
Statistical Analysis
All statistical analyses were performed using IBM SPSS
statistics, version 20. Comparison of the pre- and post- supple-
mentation condition outcome measures such as RBC PUFA,
AHR, D BPND etc., were evaluated with paired t tests and linear
mixed model with region of interest as a repeated measure and
condition as fixed factor. Relationships between the fatty acid
composition, cognitive and imaging measures were analyzed with
Pearson product moment correlation coefficient. A two-tailed
probability value of p,0.05 was selected as significant.
Results
11 subjects (5 males/6 females; all Caucasian) completed the
study. The mean age of the subjects was 2262 years. The mean
body mass index of the subjects was 25.663.5. All eleven subjects
were non-smokers.
RBC Fatty Acid Composition
The results of the RBC fatty acid composition analysis before
and after six months of n–3 PUFA supplementation are shown in
Table 1. They include the main n–3 PUFAs (DHA, EPA) and its
precursor a-linolenic acid (ALA) and the main n–6 PUFA
(arachidonic acid, AA) and its precursor linolenic acid (LA).
Compared to the pre-supplementation condition, n–3 PUFA led
to mean increases in RBC DHA and EPA of 75% and 450%
respectively, and decreases in AA of 13% at six months (p,0.05,
paired t tests, Table 1). No significant changes were observed in
the n–3 and n–6 PUFA precursors ALA and LA. Figure 1 A and B
show the increase in RBC DHA and EPA over the 6-month
duration of the study.
Working Memory Assessment
Table 2 shows the AHR for 1-, 2- and 3-back conditions before
and after n–3 PUFA supplementation. n–3 PUFA supplementa-
tion improved working memory performance (measured as AHR)
in the 3-back (p,0.05, paired t test, Table 2), but not in the 1- and
2- back conditions.
The pre-supplementation AHR on the 3-back was linearly
related to pre-supplementation RBC DHA (r = 0.74, p = 0.009, see
Figure 2A), but not EPA (r =20.11, p= 0.76, see Figure 2B).
The post-supplementation AHR on the 3-back was not related
to the post-supplementation RBC DHA (r=20.06, p = 0.86) or
EPA levels (r =20.13, p = 0.71).
There was no significant association between the change in
working memory performance (D AHR on 3-back) and change in
RBC DHA (r= 0.29, p = 0.39) or EPA (r = 0.04, p= 0.90) levels
following supplementation.
[11C]DTBZ PET Imaging
Critical PET scan parameters are listed in Table 3.
[11C]DTBZ injected dose, specific activity at time of injection,
and injected mass did not differ between the pre- and post-n–3
PUFA supplementation conditions. No significant between-condi-
tion differences were observed in the plasma free fraction and
clearance rate of [11C]DTBZ, or in [11C]DTBZ occipital cortex
distribution volume, VND measure (data available from n= 10/11
subjects, in whom venous line placement was successful).
n–3 PUFA supplementation had no significant effect on
[11C]DTBZ BPND in the striatal subdivisions [linear mixed model,
effect of condition, F(1,20) = 0.52, p= 0.48; effect of region, F(4,
80) = 285.6: p,0.001; condition-by-region interaction,
F(4, 80) = 0.63, p = 0.64]. In addition, a test of between-condition
differences in each region of interest failed to reach significance in
all five striatal subdivisions (p.0.05, paired t tests, data in Table 4).
Correlation analyses revealed no significant relationship be-
tween pre-supplementation [11C]DTBZ BPND in the striatum and
RBC DHA (r =20.40, p= 0.22) or EPA (r = 0.12, p= 0.70) levels.
Also, no significant associations were noted between the change in
[11C]DTBZ BPND in the striatum and change in RBC DHA
(r =20.29, p = 0.39) or EPA (r =20.04, p = 0.90) levels following
supplementation. No significant associations were noted when the
above correlations were performed using [11C]DTBZ BPND and D
BPND from the functional or anatomical subdivisions of the
striatum.
Omega-3 Fatty Acid Supplementation and VMAT2
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Discussion
In this study, we evaluated VMAT2 availability with
[11C]DTBZ and PET in a group of healthy young adults before
and after six months of supplementation of a FDA approved
formulation of n–3 PUFA (Lovaza, 2 g/day). Despite the fact that
the formulation used in this study led to significant elevations in
RBC DHA (1.75-fold) and EPA (4.5-fold) levels relative to pre-
supplementation values, we failed to detect an effect for it on
striatal VMAT2 availability. The mean change in [11C]DTBZ
BPND in the striatal subdivisions (range 21 to 24%) after n–3
PUFA supplementation was well within the reported test-retest
variability (4 to 7%) for this radioligand [28]. This observation in
humans is somewhat inconsistent with rodent studies that suggest
n–3 PUFA deficient animals relative to controls have 25 to 60%
less VMAT2 binding in the ventral striatum [12–14]. An
important difference that led to the inability to detect an effect
on [11C]DTBZ binding might be related to the fact that healthy
humans were supplemented with n–3 PUFA in this study, as
opposed to the rodent studies in which a group of animals were
developmentally deprived of n–3 PUFA and compared to
controls. Thus, the possibility of dietary depletion of n–3 PUFA
leading to a reduction in striatal VMAT2 availability in humans
cannot be excluded based on the six-month supplementation data.
Because individuals with diets deficient in n–3 PUFA are likely to
have less RBC DHA/EPA, we evaluated whether lower RBC
DHA/EPA levels are associated with lower striatal VMAT2
availability in subjects before supplementation. Contrary to this
hypothesis, we found no relationship between the RBC DHA/
EPA levels and striatal [11C]DTBZ BPND. Taken together these
data do not support an effect for n–3 PUFA on striatal VMAT2 in
healthy adults.
Two interesting observations are reported in this study. The first
is that in this group of young adults superior working memory
performance in the 3-back condition prior to supplementation was
correlated with higher RBC DHA. This finding is consistent with a
previous report in which higher serum DHA was related to
superior performance on tests of non verbal reasoning and
working memory in a relatively large cohort of middle aged adults
[2]. Second, there was an improvement in working memory
performance in the 3-back condition after six months of n–3
PUFA supplementation. Although, practice-effects cannot be ruled
out as the reason for this observation in this cohort, this result is
consistent with some clinical trials suggesting that n–3 PUFA (fish
oil) supplementation improves cognitive functioning in elderly
adults with mild to no cognitive impairment [33–37]. Surprisingly,
3-back performance improvement was significant despite the fact
that there was no correlation between changes in AHR and RBC
DHA/EPA levels following supplementation with n–3 PUFA. But,
when individuals were stratified into two groups based on their
pre-supplementation DHA levels (i.e., less than or greater than 3%
mol of total fatty acid pool) we found that the mean change in
AHR 3-back was 0.2960.18 in the low DHA group (n= 6
Figure 1. A and B show the increase in RBC DHA and EPA over the course of the six-month study, i.e., from pre-supplementation
levels at baseline (0-month) to post-supplementation levels prior to the [11C]DTBZ PET scan (6-months).
doi:10.1371/journal.pone.0046832.g001
Table 1. RBC fatty acid composition analysis.
Type PUFA
Pre- n3
PUFA
Post- n3
PUFA t df p-value
n–3 PUFA ALA 0.460.1 0.460.1 0.11 10 0.92
DHA 2.961.0 5.161.2 29.89 10 ,0.01
EPA 0.460.1 1.860.8 26.30 10 ,0.01
n–6 PUFA LA 21.765.1 21.963.8 20.13 10 0.90
AA 13.962.0 12.262.0 3.49 10 0.01
Values are mean and standard deviation (SD), n = 11 per condition.
p-values are from two-tailed, paired t tests; t is t statistic; df is degrees of
freedom.
doi:10.1371/journal.pone.0046832.t001
Table 2. Adjusted hit rate from the n-back working memory
task.
n-back
Pre- n3
PUFA
Post- n3
PUFA t df p-value
1-back 0.9860.04 0.9960.02 21.480 10 0.17
2-back 0.9360.10 0.9460.09 20.399 10 0.70
3-back 0.6560.27 0.8060.15 22.292 10 0.04
Values are mean and standard deviation (SD), n = 11 per condition.
p-values are from two-tailed, paired t tests; t is t statistic; df is degrees of
freedom.
doi:10.1371/journal.pone.0046832.t002
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subjects) and 20.0160.14 in the high DHA group (n= 5 subjects).
This suggests that the individuals with low pre-supplementation
DHA levels benefitted the most by the n–3 PUFA. Further
investigation in larger samples is needed to understand this
relationship.
The fact that working memory performance was enhanced by
n–3 PUFA supplementation regardless of an effect on striatal
VMAT2 suggests that its potential pro-cognitive effects, are
mediated via extrastriatal dopamine or other non-dopaminergic
mechanisms such as effects on inflammation, cellular signaling and
trafficking etc. Alternatively other mechanisms that govern the
release and storage of dopamine such as afferent regulation of
dopamine cell activity or dopamine synthesis may play a role.
Future studies are needed to investigate the role of n–3 PUFA on
dopamine release mechanisms as well as indices of prefrontal
cortical dopamine function. The latter studies are especially
critical because prefrontal cortical dopamine is linked to working
memory performance [38]. Since the concentration of dopamine
in the prefrontal cortex is 10 to 35-fold lower than in the striatum
(dopamine concentration: cortex 0.5 nM vs striatum 5–18 nM) it
is likely that a relatively small increase in dopamine following n–3
PUFA supplementation has a greater impact in the cortex and
translates to pro-cognitive effects [39,40]. In addition, the
likelihood to detect relatively small changes in dopamine
concentration is better in the prefrontal cortex than in the
striatum because of the low baseline dopamine levels in this region.
Future studies with D1 and D2/3 receptor PET radiotracers to
evaluate the effects of n–3 PUFA on prefrontal cortical dopamine
and its relationship with working memory are necessary to address
these issues.
The current investigation was designed as a proof of concept
study to clarify whether n–3 PUFA supplementation leads to
increased VMAT2 availability in the human striatum. This
question arose based on a recent PET imaging study in which
we showed that cocaine addicts have lower vesicular monoamine
transporter type 2 in the striatum relative to healthy controls [41].
This reduction in VMAT2, which suggests fewer dopamine
storage vesicles in the terminals, is one of the mechanisms that lead
to the blunted (or less) dopamine release in the striatum after a
psychostimulant challenge in cocaine addicts compared to controls
[42]. In addition, more recent data links this blunted dopamine
release in the striatum to relapse and treatment failure in cocaine
addicts [43,44]. Since preclinical studies in rodents signaled that
diets deficient in n–3 PUFAs lead to lower striatal VMAT2 density
by 25 to 60% and reduce stimulant-induced DA release [10] we
Figure 2. Shows the relationship between pre-supplementation RBC DHA or EPA in x-axis and pre-supplementation performance
(AHR) in 3-back test in y-axis. The AHR ranges from 1 (best performance) to 21 (worst performance), with a score of 0 corresponding to
performance at chance level. RBC DHA (Panel A), but not EPA (Panel B) was associated with performance in the task.
doi:10.1371/journal.pone.0046832.g002
Table 3. Scan parameters.
Parameter
Pre- n3
PUFA
Post- n3
PUFA t df
p-
value
Injected dose
(mCi)
16.060.6 16.060.5 20.09 10 0.93
SA (Ci/mmoles) 297361543 318961288 20.35 10 0.73
Injected Mass
(ug)
2.862.6 2.161.0 0.86 10 0.41
Free Fraction,
fp (%){
30.262.9 30.962.8 20.57 9 0.58
Clearance
(L/h){
72.3617.4 67.4621.0 0.70 9 0.50
Occipital VT
(mL cm-3){
3.8060.89 3.3861.05 1.31 9 0.22
Values are mean and standard deviation (SD), n = 11 per condition (unless
noted as different).
p-values are from two-tailed, paired t tests; t is t statistic; df is degrees of
freedom.
{n= 10/condition.
doi:10.1371/journal.pone.0046832.t003
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were interested in evaluating the potential of n–3 PUFA as means
to increase VMAT2 availability, enhance DA storage and release,
and prevent relapse in cocaine addicts. The result of this human
imaging study suggests that n–3 PUFA supplementation is unlikely
to enhance striatal DA transmission in cocaine addicts and
promote abstinence.
In summary, we found no effect for n–3 PUFA supplementation
on striatal VMAT2 availability in healthy humans using
[11C]DTBZ and PET. Higher RBC DHA levels were associated
with better working memory performance in this cohort of young
adults, which is consistent with that previously shown in middle-
aged adults. Also, n–3 PUFA supplementation improved working
memory performance, which is consistent with some but not all
clinical trials that have evaluated the pro-cognitive effects of n–3
PUFA in humans. Further research is warranted to elucidate the
mechanisms by which n–3 PUFA enhances cognitive performance
in healthy individuals.
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